In 2006, Merck received FDA approval for Gardasil, the first vaccine for human papillomavirus (HPV), which has been identified as the cause of cervical cancer. Merck vaccine price of $ 360 for three shots and working on the programs for Gardasil in developing countries at lower prices. Projected Gardasil sales of $ 1 billion a year and billions more if the state ordered the vaccination. Prior to approval of FDA, Merck began to develop market Gardasil and launched an intensive campaign to get the state to make the HPV vaccine for girls entering middle school compulsory. Public and private organized groups became aware of efforts Merck, however, the campaign generated a backlash against mandatory vaccination. Merck subsequently suspended his campaign and reflect on their experience in dealing with the next turn. "Hide
by David P. Baron Source: Stanford Graduate School of Business 10 pages. Publication Date: August 5, 2008. Prod. #: P57-PDF-ENG
Related Case Solutions & Analyses:
The Genuine Responsibilities of the CEO: A Framework for Managing Today
DePaul Industries in 2012: Financing Growth in a Social Venture
Preparing for Disruptions Through Early Detection
John Fahey, President and CEO of National Geographic Society, In-Class Comments, 02/11/2011, Video
Lincoln Financial Meets the Financial Crisis
Being Distinctive vs. Being Conspicuous, Gender and Performance in Groups
CEO Spotlight: Jeff Bezos
Finding the Right Role for Social Media in Innovation
ATF, Inc.: Fasteners and Family
Double Career Negotiation (B): Confidential Instructions for the Medical Doctor
